These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 18727811)

  • 21. Efficacy and Safety of Tranexamic Acid in Melasma: A Meta-analysis and Systematic Review.
    Kim HJ; Moon SH; Cho SH; Lee JD; Kim HS
    Acta Derm Venereol; 2017 Jul; 97(7):776-781. PubMed ID: 28374042
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of oral tranexamic acid on erythema index in patients with melasma.
    Nguyen J; Rajgopal Bala H; Ross A; Wong CC; Paul E; Rodrigues M
    Australas J Dermatol; 2021 May; 62(2):206-209. PubMed ID: 33125702
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epidemiology of melasma in Brazilian patients: a multicenter study.
    Hexsel D; Lacerda DA; Cavalcante AS; Machado Filho CA; Kalil CL; Ayres EL; Azulay-Abulafia L; Weber MB; Serra MS; Lopes NF; Cestari TF
    Int J Dermatol; 2014 Apr; 53(4):440-4. PubMed ID: 23967822
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of refractory dermal melasma with the MedLite C6 Q-switched Nd:YAG laser: two case reports.
    Polnikorn N
    J Cosmet Laser Ther; 2008 Sep; 10(3):167-73. PubMed ID: 18788035
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A multicenter study of topical azelaic acid 15% gel in combination with oral doxycycline as initial therapy and azelaic acid 15% gel as maintenance monotherapy.
    Thiboutot DM; Fleischer AB; Del Rosso JQ; Rich P
    J Drugs Dermatol; 2009 Jul; 8(7):639-48. PubMed ID: 19588640
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Facial skin-lightening benefits of the tetrapeptide Pro-Lys-Glu-Lys on subjects with skin types V-VI living in South Africa.
    Farwick M; Maczkiewitz U; Lersch P; Summers B; Rawlings AV
    J Cosmet Dermatol; 2011 Sep; 10(3):217-23. PubMed ID: 21896134
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Melasma.
    Wu IB; Lambert C; Lotti TM; Hercogová J; Sintim-Damoa A; Schwartz RA
    G Ital Dermatol Venereol; 2012 Aug; 147(4):413-8. PubMed ID: 23007216
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The efficacy of tranexamic acid in the treatment of melasma.
    Bagherani N
    Dermatol Ther; 2015; 28(4):265. PubMed ID: 25649261
    [No Abstract]   [Full Text] [Related]  

  • 29. [Melasma : An update on the clinical picture, treatment, and prevention].
    Becker S; Schiekofer C; Vogt T; Reichrath J
    Hautarzt; 2017 Feb; 68(2):120-126. PubMed ID: 28084498
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tranexamic acid: an important adjuvant in the treatment of melasma.
    Tse TW; Hui E
    J Cosmet Dermatol; 2013 Mar; 12(1):57-66. PubMed ID: 23438143
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Melasma pathogenesis: a review of the latest research, pathological findings, and investigational therapies.
    Rajanala S; Maymone MBC; Vashi NA
    Dermatol Online J; 2019 Oct; 25(10):. PubMed ID: 31735001
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Superiority of tacrolimus 0.1% ointment compared with fluticasone 0.005% in adults with moderate to severe atopic dermatitis of the face: results from a randomized, double-blind trial.
    Doss N; Reitamo S; Dubertret L; Fekete GL; Kamoun MR; Lahfa M; Ortonne JP
    Br J Dermatol; 2009 Aug; 161(2):427-34. PubMed ID: 19416227
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Natural options for management of melasma, a review.
    Nomakhosi M; Heidi A
    J Cosmet Laser Ther; 2018; 20(7-8):470-481. PubMed ID: 29461133
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Melasma: a clinicopathological study of 43 cases.
    Sarvjot V; Sharma S; Mishra S; Singh A
    Indian J Pathol Microbiol; 2009; 52(3):357-9. PubMed ID: 19679960
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aggravating factors for melasma: a prospective study in 197 Tunisian patients.
    Guinot C; Cheffai S; Latreille J; Dhaoui MA; Youssef S; Jaber K; Nageotte O; Doss N
    J Eur Acad Dermatol Venereol; 2010 Sep; 24(9):1060-9. PubMed ID: 20202051
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Utilizing combination therapy to optimize melasma outcomes.
    Rendon MI
    J Drugs Dermatol; 2004; 3(5 Suppl):S27-34. PubMed ID: 15552597
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Melasma: insights and perspectives.
    Jadotte YT; Schwartz RA
    Acta Dermatovenerol Croat; 2010; 18(2):124-9. PubMed ID: 20624364
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A double-blind controlled study of a nonhydroquinone bleaching cream in the treatment of melasma.
    Levy JL; Pons F; Agopian L; Besson R
    J Cosmet Dermatol; 2005 Dec; 4(4):272-6. PubMed ID: 17168876
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Estrogen receptor expression in melasma: results from facial skin of affected patients.
    Lieberman R; Moy L
    J Drugs Dermatol; 2008 May; 7(5):463-5. PubMed ID: 18505139
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical patterns and epidemiological characteristics of facial melasma in Brazilian women.
    Tamega Ade A; Miot LD; Bonfietti C; Gige TC; Marques ME; Miot HA
    J Eur Acad Dermatol Venereol; 2013 Feb; 27(2):151-6. PubMed ID: 22212073
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.